Nura reveals neuroprotective lead target, first part of its neurology one-two punch
Nura aims to prevent axon degeneration, preserve neurons starting with an axon death switch
Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen veteran Alpna Seth, the South San Francisco company is developing a small molecule that inhibits SARM1, an axon death switch.
The Column Group, which founded Nura Bio Inc. in